
Please try another search
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company’s products under pre-clinical development include RC118, RC138, RC148, RC158, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Jianmin Fang | 62 | 2008 | Co-Founder, CEO, GM, Member of Scientific Advisory Board & Executive Director |
Weidong Wang | 65 | 2013 | Co-Founder & Executive Chairman |
Jian Lin | 69 | 2008 | Executive Director |
Xianjing Hao | 58 | 2020 | Independent Non-Executive Director |
Qingkai Wen | 59 | 2020 | Executive Director & Board Secretary |
Gang Pei | - | - | Member of Scientific Advisory Board |
Lorne Alan Babiuk | 78 | 2020 | Member of Scientific Advisory Board |
Yunjin Chen | 40 | 2022 | Independent Non-Executive Director |
Guobin Huang | - | 2025 | Independent Non-Executive Director |
Marsha A. Moses | - | - | Member of Scientific Advisory Board |
Liqiang Wang | 55 | 2020 | Non-Executive Director |
Xiaodi Su | 39 | 2020 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review